WooGene B&G Co. Ltd (018620) - Total Liabilities

Latest as of September 2025: ₩50.21 Billion KRW ≈ $34.03 Million USD

Based on the latest financial reports, WooGene B&G Co. Ltd (018620) has total liabilities worth ₩50.21 Billion KRW (≈ $34.03 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore WooGene B&G Co. Ltd operating cash flow efficiency to assess how effectively this company generates cash.

WooGene B&G Co. Ltd - Total Liabilities Trend (2011–2024)

This chart illustrates how WooGene B&G Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check WooGene B&G Co. Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

WooGene B&G Co. Ltd Competitors by Total Liabilities

The table below lists competitors of WooGene B&G Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
Thanasiri Group Public Company Limited
BK:THANA
Thailand ฿579.66 Million
Trematon Capital Investments
JSE:TMT
South Africa ZAC367.68 Million
Euro Manganese Inc
AU:EMN
Australia AU$34.27 Million
High Coast Distillery AB
ST:HIGHCO-B
Sweden Skr146.26 Million
Winamp Group SA
PA:ALPET
USA €5.84 Million
Bal Pharma Limited
NSE:BALPHARMA
India Rs2.71 Billion
IntegraFin Holdings plc
LSE:IHP
UK GBX33.85 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down WooGene B&G Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of WooGene B&G Co. Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.23 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.80 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.43 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how WooGene B&G Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for WooGene B&G Co. Ltd (2011–2024)

The table below shows the annual total liabilities of WooGene B&G Co. Ltd from 2011 to 2024.

Year Total Liabilities Change
2024-12-31 ₩85.08 Billion
≈ $57.66 Million
+72.74%
2023-12-31 ₩49.25 Billion
≈ $33.38 Million
-12.37%
2022-12-31 ₩56.20 Billion
≈ $38.09 Million
+23.90%
2021-12-31 ₩45.36 Billion
≈ $30.74 Million
-4.93%
2020-12-31 ₩47.72 Billion
≈ $32.34 Million
-17.54%
2019-12-31 ₩57.87 Billion
≈ $39.22 Million
+72.55%
2018-12-31 ₩33.54 Billion
≈ $22.73 Million
-10.80%
2017-12-31 ₩37.60 Billion
≈ $25.48 Million
+4.42%
2016-12-31 ₩36.01 Billion
≈ $24.40 Million
+77.05%
2015-12-31 ₩20.34 Billion
≈ $13.78 Million
+142.38%
2014-12-31 ₩8.39 Billion
≈ $5.69 Million
+10.11%
2012-12-31 ₩7.62 Billion
≈ $5.16 Million
-5.51%
2011-12-31 ₩8.06 Billion
≈ $5.47 Million
--

About WooGene B&G Co. Ltd

KQ:018620 Korea Pharmaceuticals
Market Cap
$13.13 Million
₩19.37 Billion KRW
Market Cap Rank
#26201 Global
#1952 in Korea
Share Price
₩746.00
Change (1 day)
+4.78%
52-Week Range
₩670.00 - ₩1004.00
All Time High
₩6913.04
About

WooGene B&G Co., Ltd. develops, manufactures, and markets products to animal health and livestock industry in South Korea and internationally. The company's products include veterinary medicines, raw materials, and probiotic. It offers veterinary medicines for poultry, swine, bovine, horse, dog, cat, sheep, deer, and aquaculture markets; and vaccines for swine, poultry, canine, and cow markets. T… Read more